RPG Life Sciences Q2: net profit stands at ₹28.2 Cr on 16.5% revenue growth; API subsidiary restructuring and acquisitions shape earnings
The integrated pharmaceutical company RPG Life Sciences has closed its September quarter with strong sales growth and a major push into active ingredients. Behind the headline numbers, a high base, acquisition costs and a new investor in its API arm tell a more layered story about where earnings go next.
The Nifty 50 traded at 23,096, up 0.71%, while the Sensex is up 0.56% to 74,563 on Friday. Following this, the shares of RPG Life Sciences Ltd are trading at Rs. 2,676.90, down 10.88 percent on Friday. The stock touched the intraday high of Rs. 2,849.60 after opening at Rs. 2,812.00 before slipping to a low of Rs. 2,666. The company commands a market capitalization of Rs. 4,427.33 crore
Also Read: Krishna Defence Q2 : Net Profit Jumps 71.9% to ₹15.32 Cr, Revenue Up 30.7%; Interim Dividend Declared
What Happened in the Quarter
RPG Life Sciences announced its unaudited results for the quarter ended September 30, 2026, after a board meeting on October 29. Consolidated revenue rose to Rs. 211.6 crore, with domestic formulations at Rs. 145.7 crore, international formulations at Rs. 36.7 crore and API at Rs. 28.0 crore. During the quarter, the company moved its API business into a subsidiary, RPG Active Pharma, and bought Raghava Life Sciences’ API unit and Actis Generics.
The growth is real, but the profit picture needs context. Net profit for the quarter was Rs. 28.2 crore, down from Rs. 36.9 crore a year ago, when a Rs. 11.2 crore exceptional gain linked to a fire incident lifted earnings. Management says excluding Rs. 5.5 crore of one-off restructuring and acquisition costs, adjusted profit after tax rose 13.4 percent to Rs. 32.3 crore.
The balance sheet has changed too. Total assets climbed to Rs. 1,116.4 crore from Rs. 793.1 crore in March, helped by about Rs. 243 crore invested in the API arm by outside funds, which also adds a minority interest to equity. Borrowings stood at about Rs. 22 crore. Integration of the new plants will shape how quickly API margins improve.
Financial Performance
Looking at the quarterly results of RPG Life Sciences Limited, the company’s consolidated revenue from operations increased by 16.5 percent YoY, from Rs. 181.7 crore in Q2 FY26 to Rs. 211.6 crore in Q2 FY27, and grew by 8.2 percent QoQ from Rs. 195.7 crore in Q1 FY27.
RPG Life Sciences generated 69 percent of its revenue from domestic formulations, 17 percent from international formulations and 13 percent from API sales in Q2 FY27.
In Q2 FY27, RPG Life Sciences’ consolidated net profit decreased by 23.4 percent YoY, reaching Rs. 28.2 crore compared to Rs. 36.9 crore during the same period last year. As compared to Q1 FY27, the net profit has decreased by 7.7 percent, from Rs. 30.6 crore.
The basic earnings per share decreased by 23.4 percent and stood at Rs. 17.07 as against Rs. 22.28 recorded in the same quarter in the previous year, FY2026.
About the Company
RPG Life Sciences is an integrated pharmaceutical company, part of the RPG Group, with a history of more than 50 years. It sells branded formulations in India, generics abroad and synthetic APIs across more than 60 countries. Brands such as Azoran, Aldactone, Lomotil and Naprosyn anchor its portfolio, and it also runs five manufacturing facilities with more than 1,800 employees.